Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Volanesorsen in Familial Chylomicronemia Syndrome
2015-003755-21Phase 3Completed
- Sponsor
- Akcea Therapeutics
- Start
- Feb 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of volanesorsen in primary chylomicronemia (FCS), sponsored by Akcea Therapeutics. Primary endpoints: Safety of extended volanesorsen dosing and Efficacy of volanesorsen dosing. Started Feb 2016; status: completed.
02
Drugs
volanesorsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2015-003755-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003755-21.